HLTH - Cue Health to Participate at the BTIG MedTech Digital Health Life Science & Diagnostic Tools Conference
Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024.
About Cue Health
Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. The Cue Health platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue’s customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive this FDA approval. Cue also received Emergency Use Authorization from the FDA for its molecular Mpox test at the point-of-care. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131854025/en/
Press
Cue Health press@cuehealth.com
Investors
ICR Westwicke
Caroline Corner
+1-415-202-5678
caroline.corner@westwicke.com